7 19 2016 290 3,200 1,900 2,500 1
104% 1.782 8,730 800 730 310 9,000 1. 3,190 2. 690 3. 6,000 4. 50/50 7,690 3,110 7,390 156% 5,200 2,030 AstraZeneca AB publ Nutrition Science Partners Limited 83% 3802,220 41% 6,410 4,550 677 249 428 19 40% 11% 5.189 4.654 11% 10% 2,520 2,280 170 2
99.8% Hutchison MediPharma Holdings Limited12.24% 5.69% 5b 7 19 3 c-met 9 Tagrisso T790M c-met 109 PRCC PRCC HMPL-523 (Syk) B 3
5b 7 19 3 4.7 =0.30 p<0.001 1.0 FALUCA 3,310 30% 44.4% 10% 6.4% b 81 SANET-ep EGFR b 4
40% 2.866 2.049 20% 1,590 1,320 20 15% 1.593 56% 100 2,110 90% 1.05 3,110 2016 FDA 2016 FDA b PRCC FDA PRCC FDA EGFR Tagrisso Iressa c-met b 5
2016 HMPL-523 Syk FRESCO b Taxol SANET-p b b HMPL-689 3 delta HMPL-453 6
1 2 3 8 12 31 33 39 49 50 52 53 54 55 57 7